Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
about
Combined oral contraceptives: venous thrombosisDifferent combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysisRisk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9New insights into the biology of tissue factor pathway inhibitorHormonal contraception and venous thromboembolismThird generation oral contraceptives and risk of venous thrombosis: meta-analysisThe progestin levonorgestrel induces endothelium-independent relaxation of rabbit jugular vein via inhibition of calcium entry and protein kinase C: role of cyclic AMPFactor V Leiden related Budd-Chiari syndromeDrospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.Effects of oral contraceptives on selected parameters of the homeostatic control system in young women having a sudden disorder of the auditory and/or balance system.International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).Biology of tissue factor pathway inhibitor.The investigation and management of inherited thrombophilia.Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptivesBenefits and risks of third-generation oral contraceptives.Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed.Pharmacodynamics of oestrogens and progestogens.Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism.Oral contraceptives, hormone replacement therapy and haemostasis.The association between drospirenone and hyperkalemia: a comparative-safety studyFactor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.Factor V Leiden thrombophilia.Management of inherited thrombophilia: guide for genetics professionals.The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy.Examining the use of oral contraceptives in the management of acne.Gene-environment interactions in human diseases.Current reversible contraceptive methods: a global perspective.Hormonal contraception and thrombotic risk: a multidisciplinary approach.Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.Risk factors for venous and arterial thrombosisPharmacology of progestogens used in oral contraceptives: an historical review to contemporary prescribing.Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in FranceEstrogens, progestogens and thrombosis.Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.Combined oral contraceptives, smoking, and cardiovascular risk.Hormones and pregnancy: thromboembolic risks for women.Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control studyVenous thromboembolism: disease burden, outcomes and risk factors.Factor V Leiden: should we screen oral contraceptive users and pregnant women?
P2860
Q24198113-1817FEE3-713F-4A96-B800-A94223B16BDBQ24624180-624CF05C-13C8-4AB6-A0AD-D2FA738D54A6Q24634077-F5E378DF-41CD-4B10-BE8B-1E0C7EFCAF88Q26865048-936815E9-94C9-44AD-9F89-E3FD43F81858Q28266187-6EE010A2-6C9B-4259-B463-CF8267F74D65Q28344562-AA46FCA5-CCBA-411E-A97E-A5C02B06FCE5Q28344628-22E8E406-3C85-4EA2-BC82-B9C0D130C0C7Q28345961-84039908-621E-4481-8A68-41655D70BDDFQ30235365-4DB48424-DA19-452E-82B9-62426D21B215Q30420494-6A7E521C-3E9E-4A83-8B79-20AA940FE82DQ30891586-65233D6D-D910-4748-B69F-1579C49B47C1Q33585249-B6FFD9EE-FFD6-4759-9CDD-46E910A0EBD6Q33643586-9CCAC983-29C9-47F3-BE89-AC47DAFE77A6Q33704721-662FC760-3050-405D-8892-23EB21B1D7D3Q33778866-D5F5A6ED-FD67-4716-844F-7762411395A0Q33799389-6B3E5302-7775-4497-898A-28F521B574F9Q33918549-9187B16E-4CE0-411C-9966-341926D30F83Q33932536-307AF788-C57A-4667-B410-E80755DB37F2Q34039827-162F1B92-77B6-4D15-8913-B2E2CBC89C93Q34114759-97FF9DD4-8B9B-4EFC-A8A4-99F0B441AE22Q34128442-455C623E-C64E-42EC-994D-CC67336FAAE1Q34152374-002B0CA5-A58E-4279-A2D9-003783E27F39Q34195599-05A4E4BC-32AC-4615-84C4-A556C2BBEBEDQ34215860-113CA737-AAAA-43B6-B452-957BBFE8B222Q34227082-A5ADBF40-F6CC-4378-B2F4-8079C817CCB1Q34272111-CFE77EB5-173C-4A4F-9555-59B0168F8301Q34407923-F5B0E81E-9A51-498A-9376-E827D15A4B62Q34478867-08571078-8621-4AFF-A351-BDB1F6B8C655Q34513007-EE607DAA-A543-47E3-A39E-3BB4C34A8A6AQ34836664-19D280EA-5E3C-4381-8D82-FE4792562CA4Q34988616-9A90AAE2-02CD-48A3-A011-6CAF3E3C93ACQ35130599-B66C912C-C4CA-4A6F-96D9-88C1FBAC0D22Q35153912-60683900-1176-4798-B9E4-711602E7F98DQ35181580-59DE412E-A56A-4ADF-8E55-7DE975CB4C2EQ35369291-31A5D8FE-3653-46B5-8CA9-816A4CECEACEQ35558094-A4D05D87-A409-4A82-8AD4-F8E9CAD31A1DQ35852845-AE533D5A-82AD-45E7-A486-B83BC236DE87Q36199544-95955AC6-F6EF-48B1-8914-6E8732D8DD02Q36230821-800C49B2-0419-44AC-B101-A800918567AEQ36600956-D51BF649-A5F3-467C-812F-469BC28963BE
P2860
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Enhancement by factor V Leiden ...... third-generation progestagen.
@en
Enhancement by factor V Leiden ...... third-generation progestagen.
@nl
type
label
Enhancement by factor V Leiden ...... third-generation progestagen.
@en
Enhancement by factor V Leiden ...... third-generation progestagen.
@nl
prefLabel
Enhancement by factor V Leiden ...... third-generation progestagen.
@en
Enhancement by factor V Leiden ...... third-generation progestagen.
@nl
P2093
P1433
P1476
Enhancement by factor V Leiden ...... third-generation progestagen.
@en
P2093
F M Helmerhorst
F R Rosendaal
H R Büller
J P Vandenbroucke
K W Bloemenkamp
P304
P356
10.1016/S0140-6736(95)91929-5
P407
P577
1995-12-01T00:00:00Z